Cases & Deals

  • Home
  • Practices
  • Kowa Pharmaceuticals America announces agreement with CymaBay Therapeutics to license gout compound

Share

Kowa Pharmaceuticals America announces agreement with CymaBay Therapeutics to license gout compound

January 2017

Client(s) Kowa Company, Ltd.

Jones Day advised Kowa Company, Ltd. and its subsidiary Kowa Pharmaceuticals America, Inc. in a license agreement with CymaBay Therapeutics for exclusive U.S. rights to Arhalofenate, a compound in late stage clinical development for the treatment of gout.

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.